Evidence map›Paper›PMID 31439817›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2019

An in situ high-throughput screen identifies inhibitors of intracellular

Philip L Bulterys, Isabelle J Toesca, Michael H Norris, Jeffrey P Maloy, Sorel T Fitz-Gibbon, Bryan France, Babak Toffig, Marco Morselli, Nawarat Somprasong, Matteo Pellegrini and 5 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Sensing of intracellular Hcp levels controls T6SS expression inProceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Philip L BulterysUniversity of California, Los Angeles-California Institute of Technology Medical Scientist Training Program, David Geffen School of Medicine, University of California, Los Angeles, CA 90095.
Isabelle J ToescaDepartment of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, CA 90095.
Michael H NorrisDepartment of Infectious Diseases and Immunology, College of Veterinary Medicine, University of Florida, Gainesville, FL 32611.
Jeffrey P MaloyDepartment of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, CA 90095.
Sorel T Fitz-GibbonDepartment of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, CA 90095.ORCID 0000-0001-7090-5719
Bryan FranceCalifornia NanoSystems Institute, University of California, Los Angeles, CA 90095.
Babak ToffigCalifornia NanoSystems Institute, University of California, Los Angeles, CA 90095.
Marco MorselliDepartment of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, CA 90095.
Nawarat SomprasongEmerging Pathogens Institute, University of Florida, Gainesville, FL 32611.
Matteo PellegriniDepartment of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, CA 90095.
Herbert P SchweizerEmerging Pathogens Institute, University of Florida, Gainesville, FL 32611.
Apichai TuanyokDepartment of Infectious Diseases and Immunology, College of Veterinary Medicine, University of Florida, Gainesville, FL 32611.
Robert DamoiseauxCalifornia NanoSystems Institute, University of California, Los Angeles, CA 90095.
Christopher T FrenchDepartment of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, CA 90095; ctfrench@ucla.edu jfmiller@g.ucla.edu.
Jeff F MillerMolecular Biology Institute, University of California, Los Angeles, CA 90095; ctfrench@ucla.edu jfmiller@g.ucla.edu.
California NanoSystems Institute · USUniversity of California, Los Angeles · USUniversity of Florida · USCalifornia Institute of Technology · US

Funding

Vaccines and Diagnostics TrialsU54AI065359 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BARBOUR, ALAN G. · 2005 to 2013
$88.8M
UCLA-Caltech Medical Scientist Training ProgramT32GM008042 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AJIJOLA, OLUJIMI A, DAWSON, DAVID WAYNE · 1985 to 2023
$29.9M
UCLA NIGMS T32 Program AssessmentT32GM007185 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TORRES, JORGE · 1985 to 2020
$21.7M
Intercellular spread of Burkholderia and novel therapeutic strategiesF30AI118342 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BULTERYS, PHILIP L. · 2016 to 2018
$132k
NIAID NIH HHS F30 AI118342NIAID NIH HHS U54 AI065359NIGMS NIH HHS T32 GM007185NIGMS NIH HHS T32 GM008042
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug RepositioningAnimalsBurkholderia pseudomalleiCiprofloxacinCytoplasmDisease Models, AnimalDrug Evaluation, PreclinicalFemaleFlucytosineHEK293 CellsHigh-Throughput Screening AssaysHumansMelioidosisMiceMicrobial Sensitivity TestsTreatment OutcomeCiprofloxacinFlucytosineBurkholderia pseudomalleidrug discoverymelioidosissmall moleculetype 6 secretion system (T6SS)

Identifiers

PMID31439817
PMCPMC6744847
OpenAlexW2969688880

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.